News
The Python development team has announced the arrival of 3.14's first release candidate before its official launch in October ...
Replimune (REPL) stock rebounds even as FDA rejection of its RP1 skin cancer drug lead to multiple analyst downgrades on Wall Street. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback